<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05008042</url>
  </required_header>
  <id_info>
    <org_study_id>EUDRACT 2015-005086-23</org_study_id>
    <nct_id>NCT05008042</nct_id>
  </id_info>
  <brief_title>Evaluation of the Efficiacy of Mecobalamine in the Treatment of Long-term Pain in Women Diagnosed With Fibromyalgia</brief_title>
  <official_title>Evaluation of the Efficiacy of Mecobalamine (Vit B12) in the Treatment of Long-term Pain in Women Diagnosed With Fibromyalgia: Single-blind Randomized Controlled Trial With Three-month Follow up</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Linnaeus University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Landstinget i Kalmar Län</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Region Östergötland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kronoberg County Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Linnaeus University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fibromyalgia causes long term pain where mostly women are affected. It is not entirely clear&#xD;
      how vitamin B12 affects the human pain system, there are however many primary studies that&#xD;
      indicate different interesting approaches. Considering that the receptor of NMDA is involved&#xD;
      in both long-term pain and vitamin B12 deficiency its of most importance to evaluate whether&#xD;
      vitamin B12 decreases the pain sensitivity and the experience of pain i.e hyperalgesia and&#xD;
      allodynia, at persons with fibromyalgia.The aim of this study is therefore to evaluate the&#xD;
      effect of Mecobalamin (vitamin B12), and describe lived experiences of pain, health,&#xD;
      suffering and well-being in women with diagnosed fibromyalgia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 6, 2019</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized controlled trial with Three-month follow up</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tolerance time</measure>
    <time_frame>24 weeks</time_frame>
    <description>Primary outcome is tolerance time, maximized to Three minutes, tested using the Cold Pressure test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain experience measured by a pressure algometry test</measure>
    <time_frame>24 weeks</time_frame>
    <description>Pain experience measured by a pressure algometry test performed on the shoulder, hip, knee and elbow.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Possible pain change measured by a pressure algometry test</measure>
    <time_frame>24 weeks</time_frame>
    <description>Possible pain change measured by a pressure algometry test performed on the shoulder, hip, knee and elbow.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective experience of pain measured using Numeric Rating Scale (NRS)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Subjective experience of pain measured using Numeric Rating Scale (NRS) 0-10 where 0 is the best outcome .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Possible pain change measured using Numeric Rating Scale (NRS) 0-10</measure>
    <time_frame>24 weeks</time_frame>
    <description>Possible pain change measured using Numeric Rating Scale (NRS) 0-10 where 0 is the best outcome .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratings of expectation, desire for relief, using Numeric Rating Scale (NRS)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Ratings of expectation, desire for relief, using Numeric Rating Scale (NRS) 0-10 where 0 is the best outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratings of expectation, pain variability, using Numeric Rating Scale (NRS) 0-10</measure>
    <time_frame>24 weeks</time_frame>
    <description>Ratings of expectation, pain variability, using Numeric Rating Scale (NRS) 0-10 where 0 is the best outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activity level, assessed using questionnaire McGills Pain Questionnaire (MPQ).</measure>
    <time_frame>24 weeks</time_frame>
    <description>Activity level are assessed using questionnaire McGills Pain Questionnarie (MPQ). Short version score 0-45.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life are assessed using questionnaires RAND-36.</measure>
    <time_frame>24 weeks</time_frame>
    <description>Quality of life are assessed using questionnaires RAND-36 score 0-100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Experience of the effect of the drug, assessed using questionnaire Patients´ Global Impression of Change (PGIC).</measure>
    <time_frame>24 weeks</time_frame>
    <description>Experience of the effect of the drug, score 1-7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cobalamin in plasma</measure>
    <time_frame>24 weeks</time_frame>
    <description>Control of vitamin B12 is done by measuring cobalamin in plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lived experiences of pain, health, suffering and well-being.</measure>
    <time_frame>24 weeks</time_frame>
    <description>Qualitative in-depth interviews will be conducted to capture women's lived experiences of pain, health, suffering and well-being.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Fibromyalgia</condition>
  <arm_group>
    <arm_group_label>Mecobalamine 5 mg/ml</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The active substance of vitamin B12 given in the study is Mecobalamin 5mg / ml 2 ml ie 10 mg and is given intramuscularly.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NaCl 9mg/ml</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo substance given in the study is Sodium Chloride (NaCL) 9 mg / ml 2 ml, isotonic solution for parenteral use (Baxter) given intramuscularly.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mecobalamin 5 MG</intervention_name>
    <description>The Active substance of vitamin B12 is Mecobalamin 5 mg/ml is given intramuscularly</description>
    <arm_group_label>Mecobalamine 5 mg/ml</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Comparator : NaCl 9 mg/ml</intervention_name>
    <description>Sodium Chloride (NaCL) 9 mg / ml 2 ml, isotonic solution for parenteral use (Baxter) is given intramuscularly.</description>
    <arm_group_label>NaCl 9mg/ml</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women aged 20-70 years&#xD;
&#xD;
          -  Swedish-speaking&#xD;
&#xD;
          -  Diagnosis of fibromyalgia&#xD;
&#xD;
          -  Safe method of contraception&#xD;
&#xD;
          -  Cobalamin / p (vitamin B12) should be &gt;250 pmol/L &lt; 800 pmol/L&#xD;
&#xD;
          -  Given consent to participate.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous treatment with B12&#xD;
&#xD;
          -  Known hypersensitivity to the active substance Mecobalamin or an additive&#xD;
&#xD;
          -  Vegan as veganism can lead to B12 deficiency&#xD;
&#xD;
          -  Neuroleptics&#xD;
&#xD;
          -  Known heart, kidney or liver disease&#xD;
&#xD;
          -  Reynaud's phenomenon (white fingers)&#xD;
&#xD;
          -  Known neuropathy (impaired sensation)&#xD;
&#xD;
          -  Breastfeeding&#xD;
&#xD;
          -  Pregnancy or plan pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carina Elmqvist, Ass prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Linnaeus University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carina Elmqvist, Ass prof</last_name>
    <phone>+46772288000</phone>
    <email>carina.elmqvist@lnu.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Karin Säll Hansson, Master of sc</last_name>
    <phone>+46772288000</phone>
    <email>karin.sall_hansson@lnu.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Linnaeus University</name>
      <address>
        <city>Växjö</city>
        <state>Kronoberg</state>
        <zip>352 91</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carina Elmqvist, Ass prof</last_name>
      <phone>+46772288000</phone>
      <email>carina.elmqvist@lnu.se</email>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 30, 2021</study_first_submitted>
  <study_first_submitted_qc>August 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2021</study_first_posted>
  <last_update_submitted>August 20, 2021</last_update_submitted>
  <last_update_submitted_qc>August 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Linnaeus University</investigator_affiliation>
    <investigator_full_name>Carina Elmqvist</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <keyword>Fibromyalgia,</keyword>
  <keyword>Chronic pain,</keyword>
  <keyword>Mekobalamin,</keyword>
  <keyword>Randomized Controlled Trial</keyword>
  <keyword>VitaminB12</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibromyalgia</mesh_term>
    <mesh_term>Myofascial Pain Syndromes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

